Thromboembolic Disorders

Clopidogrel + Aspirin Cuts Ischemic Events in Stroke, TIA

May 18, 2018

The researchers found that major ischemic events occurred in 5.0 and 6.5% of patients receiving clopidogrel plus aspirin vs aspirin plus placebo, respectively (hazard ratio, 0.75); most events occurred during the first week after the initial event.

Alteplase Good for Ischemic Stroke With Unknown Onset Time

May 17, 2018

The researchers found that 53.3 and 41.8% of the alteplase and placebo groups, respectively, had a favorable outcome at 90 days (adjusted odds ratio, 1.61).

Oral Anticoagulant Effective in Recurrent VTE Prevention in Cancer Patients

By May 11, 2018

At the end of 6 months, the rate of VTE recurrence was 4% among rivaroxaban patients vs 11% in the dalteparin arm (hazard ratio [HR] 0.43, 95% CI: 0.19 to 0.99).

Osteoporosis Drug Shows Cardioprotective Potential at 10-Year Follow-Up

By May 11, 2018

The 1-year cardiovascular mortality hazard ratio (HR) for alendronate users was 0.33 (95% CI, 0.17 to 0.65) and 0.55 for incident myocardial infarction (95% CI, 0.34 to 0.89).

Long-Term Cardiovascular Risk for Endometrial Cancer Survivors

May 08, 2018

The researchers found that there were increased cardiovascular risks among endometrial cancer survivors for phlebitis, thrombophlebitis, and thromboembolism (hazard ratio, 2.07); pulmonary heart disease (hazard ratio, 1.74); and atrial fibrillation (hazard ratio, 1.5).

Andexxa Approved for Reversing Anticoagulant Activity of Rivaroxaban, Apixaban

By May 04, 2018

Andexxa, a recombinant modified human Factor Xa (FXa) protein, was approved under the FDA's Accelerated Approval pathway.

Frequency of Sauna Bathing Linked to Reduced Stroke Risk

May 03, 2018

Reduced risk seen after adjustment for CV risk factors, physical activity, socioeconomic status

Tenecteplase is superior to alteplase as neoadjuvant treatment for mechanical thrombectomy

May 01, 2018

When treated with tenecteplase, stroke patients eligible for mechanical thrombectomy had higher rates of reperfusion and superior clinical outcomes at 90 days relative to patients treated with alteplase.

Sickle cell trait not linked to increased risk of ischemic stroke

April 27, 2018

In this meta-analysis of prospective population-based studies, sickle cell trait (SCT) was not associated with any difference in risk of first ischemic stroke.

Drug-Related Endocarditis Cases Up From 2007 to 2015

April 27, 2018

Most cases were insured by federal and/or state programs (73.6 and 10.1%, respectively), but many (44.9%) patients were considered under-insured. In 2015, hospital charges of $4,580,786.88 were identified for the 66 cases of illicit drug-associated endocarditis.

Tenecteplase Appears Superior to Alteplase After Ischemic Stroke

April 26, 2018

The researchers found that the primary outcome occurred in 22 and 10% of those treated with tenecteplase and alteplase, respectively

Understanding in-hospital mortality after stroke in pediatric patients

April 25, 2018

Findings suggested that the rate of in-hospital mortality after pediatric stroke was 1.5% for neonates and 3.1% in children/adolescents. The authors also found that the strongest risk factors for mortality were congenital heart disease and stroke that involved both anterior and posterior circulation.

Carvedilol vs Metoprolol: Mortality Risk Examined Among Hemodialysis Patients

By April 18, 2018

Results showed that compared to metoprolol, those who initiated carvedilol had a greater all-cause (HR, 1.08; 95% CI,1.02-1.16) and cardiovascular mortality (HR, 1.18; 95% CI, 1.08-1.29).

Review: Lowest Mortality Risk Seen With ≤100g Alcohol/Week

April 13, 2018

"These data support limits for alcohol consumption that are lower than those recommended in most current guidelines," the authors write.

Coffee Consumption Cuts Coronary Artery Calcification

April 05, 2018

The researchers identified significant inverse associations between coffee consumption (more than 3 cups/day) and CAC ≥100 (odds ratio, 0.33 for more than three cups/day).

Outcomes-Based Pricing Doesn't Cut Costs of PCSK9 Inhibitors

April 03, 2018

"Although outcomes-based pricing may have a role in other settings, our analysis of its application to PCSK9 inhibitors - effective preventive medications with a high price tag - shows the potential limitation of this approach for high-cost preventive therapies," the authors write.

Lower Thromboembolic Risk With New A-Fib After CABG Versus NVAF

March 29, 2018

The researchers found that oral anticoagulation therapy was initiated within 30 days post-discharge in 8.4 and 42.9% of those with POAF and NVAF, respectively.

What Areas of Health are Affected Most Post-Ischemic Stroke?

March 29, 2018

Patients with higher modified Rankin Scale (mRS) levels had worse scores, though the association between scores and mRS level varied. Physical function, satisfaction with social roles, and executive function were the most affected domains.

Tresiba Label Updated With Data on Severe Hypoglycemia, CV Outcomes

By March 26, 2018

The Tresiba label was updated to reflect safety outcomes from the DEVOTE trial.

Environmental Lead Exposure May Increase CVD Mortality Risk

March 16, 2018

Environmental lead exposure tied to all-cause, cardiovascular disease, ischemic heart disease mortality

Comparative Safety of NSAIDs Among Clopidogrel Users Investigated

By March 15, 2018

Using Medicaid claims from 5 states (1999-2010) and Medicare claims for dual-enrollees, study authors analyzed the first concomitant use of clopidogrel and 1 of 10 selected NSAIDs (ibuprofen, celecoxib, naproxen, rofecoxib, meloxicam, diclofenac, indomethacin, valdecoxib, nabumetone, etodolac) after a 1-year baseline period.

Cocaine/Marijuana May Up Mortality in Younger MI Patients

March 13, 2018

Cocaine and/or marijuana use present in 10.7% of myocardial infarction patients age ≤50 years

Dabigatran Cuts Risk of Major CV Complications in Patients With MINS

By March 13, 2018

The primary efficacy outcome was the combined rate of death from a cardiovascular cause, heart attack, stroke due to inadequate blood supply, blood clots or amputation due to cardiovascular disease.

Alirocumab Tied to Reduced Risk of CV Events, Death in High-Risk Patients

By March 12, 2018

The ODYSSEY Outcomes trial (N=18,924) evaluated the effect of alirocumab on the occurrence of MACE in patients who had an ACS between 1-12 months prior to trial enrollment, and who were already taking maximally-tolerated statins (atorvastatin or rosuvastatin).

Ticagrelor vs Clopidogrel: TIMI Major Bleed Rates Compared Post-Fibrinolysis

By March 12, 2018

After 30 days of treatment the analysis found that major bleeding - the most common complication with blood thinners - occurred at the same level (0.7%) for patients in both treatment groups

Aspirin comparable to rivaroxaban for extended venous thromboembolism prophylaxis following arthroplasty

February 23, 2018

Patients initially treated with rivaroxaban following total knee or hip arthroplasty experienced similar rates of venous thromboembolism (VTE) regardless of continued rivaroxaban use or switching to aspirin for extended VTE prophylaxis.

Thrombectomy improves functional outcomes for imaging screened patients 6 to 16 hours after stroke

February 23, 2018

Patients presenting with ischemic stroke 6 to 16 hours after they were last known to be well had improved functional outcomes at 90 days if treated with thrombectomy and medical therapy compared to medical therapy alone.

FDA: Antibiotic Linked to Increased Risk of Death in Heart Disease Patients

By February 22, 2018

The Agency is asking healthcare professionals to use caution before prescribing the antibiotic to this patient population.

Cardiovascular Risk Compared Among COX-2 Selective, Nonselective NSAIDs

By February 22, 2018

Results showed the crude hazard ratio (HR) of major cardiovascular events was 1.99 (95% CI, 1.28-3.09) for COX-2 vs. nonselective NSAIDs.

Retinal Images Can Be Used to Predict CV Risk, Says Google Study

By February 22, 2018

The model used retinal images to predict cardiovascular risk.